Original Publication Date: 1 July, 2014
Publication / Source: Hepatic Oncology
Authors: Kristen K Ciombor, Richard M Goldberg
With the advent of new drugs and therapeutic combinations for metastatic colorectal cancer, the prognosis for this often incurable disease is improving. In addition to traditional cytotoxic chemotherapeutics, targeted biologic therapies, such as cetuximab, panitumumab, bevacizumab, aflibercept and regorafenib, are significantly impacting the treatment of this disease. Recent investigations have focused on determination of the optimal usage of these biologic therapies, but many controversies still exist.